Deferoxamine

Deferoxamine works in treating iron toxicity by binding trivalent (ferric) iron, forming ferrioxamine, a stable complex which is eliminated via the kidneys. 100 mg of deferoxamine is capable of binding approximately 8.5 mg of trivalent iron. Deferoxamine also works in treating aluminum toxicity by binding to tissue-bound aluminum to form aluminoxamine, a stable, water-soluble complex.

• Acute iron intoxication
• Chronic iron overload due to transfusion-dependent anemias
• Diagnosis of aluminum overload
• Chronic aluminum overload in End-Stage Renal Failure

Deferoxamine binds trivalent (ferric) iron, forming ferrioxamine, a stable complex which is eliminated via the kidneys. 100 mg of deferoxamine is capable of binding approximately 8.5 mg of trivalent iron.

Deferoxamine binds to excess iron in the body, forming a stable complex that is excreted via the kidneys, reducing the risk of organ damage.

Adult - Chronic iron overload: Subcutaneous or intravenous infusion. Dose is individualized. Maximum 6.0 grams in 24 hours.
Child: Dose is based on weight and clinical condition.

This medicine is given parenterally (subcutaneous, intramuscular or intravenous) by a healthcare professional. Kindly do not self administer.

Deferoxamine is an injection medicine given by healthcare professionals. You cannot miss a dose yourself. Do not miss your appointments with your doctor.

Common: Flushing (sense of warmth in face, ears, neck and trunk), rash, decreased blood pressure, abdominal pain.
Serious: Visual and auditory disturbances, renal dysfunction, anaphylactoid reactions.

Rapid IV injection (exceeding 15 mg/kg/h) has produced flushing, urticaria, hypotension and shock. Caution while driving (dizziness, visual disturbances). Caution with Vitamin C (avoid high doses in heart failure patients).

Hypersensitivity (except where desensitization is successful).

Prochlorperazine: May lead to temporary impairment of consciousness.
Vitamin C: May enhance iron complex excretion (150-250 mg/day); higher doses produce no additional effect.
Erythropoietin: Dose adjustment may be needed.

It is not known whether it is safe to consume alcohol with Deferoxamine. Please consult your doctor.

Deferoxamine may be unsafe during pregnancy. Animal studies have shown reproductive toxicity. Should only be used if hazard of acute iron intoxication is greater than teratogenic hazard.

It is not known whether Deferoxamine passes into breast milk. A decision should be made whether to discontinue nursing or discontinue the drug.

Pediatric dose is based on weight and clinical condition.

Elderly patients require caution due to decreased renal function.

Renal impairment: Use with caution. Not recommended in severe kidney disease.
Hepatic impairment: Limited information available. Please consult your doctor.

Since Deferoxamine is available only for parenteral administration, acute intoxication is unlikely to occur.

Store between 15-25°C. Do not store above 25°C.

Deferoxamine